Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text stands as the only available reference to assemble, review, and synthesize the latest studies on translational therapies.
Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text stands as the only available reference to assemble, review, and synthesize the latest studies on translational therapies.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
KENNETH C. ANDERSON is the Kraft Family Professor of Medicine, Harvard Medical School, Boston, Massachusetts; Director, Jerome Lipper Multiple Myeloma Center; and Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, Massachusetts. A member of the Translational Research Working Group of the National Cancer Institute and the American Society of Clinical Oncology Translational Research Task Force, Dr. Anderson is a member of numerous societies, including the American Society for Blood and Marrow Transplantation and the American Association for Cancer Research, among other organizations. Dr. Anderson is the author, coauthor, or editor of a vast array of journal articles, book chapters, and invited lectures. Dr. Anderson received the M.D. degree from the Johns Hopkins University School of Medicine, Baltimore, Maryland. IRENE M. GHOBRIAL is on Active Staff, Dana-Farber Cancer Institute, Boston, Massachusetts. The recipient of the ASCO Career Development Award (ASCO-CDA) (2006), Dr. Ghobrial is a member of the American Society of Hematology and the American Society of Clinical Oncology, among other organizations. Dr. Ghobrial is the author, coauthor, or editor of numerous professional publications, and received the M.D. degree from Cairo University, Egypt.
Inhaltsangabe
Molecular Biology, Cytogentics. Molecular Mechanisms of Growth. Animals Models in MM. Role of bone marrow microenvironment in pathogenesis of multiple myeloma. Myeloma Bone Disease. Niches within the Mutiple Myeloma bone marrow microenviriment. Novel Therapeutic Targets in MM. Monoclonal Gammopathy of Undetermined Significance. Prognostic Factors and Classification in Mutiple Myeloma. Novel Agents for Previously Untreated Mutiple Myeloma. Novel Options of Therapy- - Relapsed. High Dose Therapy in MM. Promising New Agents in phase I and II clinical trials in Multiple Myeloma. Immunotherapy in MM. Novel Therapeutic Options in Primary Systemic Amyloidosis. Novel Options of therapy in Waldenstrom Macroglobulinemia.
Molecular Biology, Cytogentics. Molecular Mechanisms of Growth. Animals Models in MM. Role of bone marrow microenvironment in pathogenesis of multiple myeloma. Myeloma Bone Disease. Niches within the Mutiple Myeloma bone marrow microenviriment. Novel Therapeutic Targets in MM. Monoclonal Gammopathy of Undetermined Significance. Prognostic Factors and Classification in Mutiple Myeloma. Novel Agents for Previously Untreated Mutiple Myeloma. Novel Options of Therapy- - Relapsed. High Dose Therapy in MM. Promising New Agents in phase I and II clinical trials in Multiple Myeloma. Immunotherapy in MM. Novel Therapeutic Options in Primary Systemic Amyloidosis. Novel Options of therapy in Waldenstrom Macroglobulinemia.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826